ArticleClinical journal of the American Society of Nephrology : CJASN2022

Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.

Phil McEwan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.